A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome

Amber Dahlin, Matthias Wittwer, Melanie De La Cruz, Jonathan M. Woo, Rujuta Bam, Valeska Scharen-Guivel, John Flaherty, Adrian S. Ray, Tomas Cihlar, Samir K. Gupta, Kathleen M. Giacomini

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Background: Tenofovir disoproxil fumarate (TDF) is a widely used antiretroviral agent with favorable efficacy, safety, and tolerability profiles. However, renal adverse events, including the rare Fanconi syndrome (FS), may occur in a small subset of patients treated for HIV infections. OBJECTIVES: The aim of this study was to identify genetic variants that may be associated with TDF-associated FS (TDF-FS). METHODS: DNA samples collected from 19 cases with TDF-FS and 36 matched controls were sequenced, and genetic association studies were conducted on eight candidate genes: ATP-binding cassette (ABC) transporters ABCC2 (MRP2) and ABCC4 (MRP4), solute carrier family members SLC22A6 (OAT1) and SLC22A8 (OAT3), adenylate kinases 2 (AK2) and 4 (AK4), chloride transporter CIC-5 CLCN5, and Lowe syndrome protein OCRL. The functional effects of a single nucleotide polymorphism (SNP) predicted to alter the transport of tenofovir were then investigated in cells expressing an identified variant of ABCC4. Results: The case group showed a trend toward a higher proportion of rare alleles. Six SNPs in ABCC2 (three SNPs), ABCC4 (one SNP), and OCRL (two SNPs) were associated with TDF-FS case status; however, this association did not remain significant after correction for multiple testing. Six SNPs, present in OCRL (four SNPs) and ABCC2 (two SNPs), were significantly associated with increased serum creatinine levels in the cases, and this association remained significant after multiple test correction (P<2×10). One synonymous SNP in ABCC2 (rs8187707, P=2.10×10, β=-73.3ml/min/1.73m) was also significantly associated with the decreased estimated glomerular filtration rate of creatinine among cases. However, these results were driven by rare SNPs present in a small number of severely affected cases. Finally, a previously uncharacterized, nonsynonymous SNP, rs11568694, that was predicted to alter MRP4 function had no significant effect on tenofovir cellular accumulation in vitro. Conclusion: Although no single predictive genetic marker for the development of TDF-FS was identified, the findings from our study suggest that rare variants in multiple genes involved in the renal handling of tenofovir, and/or renal cell homeostasis, may be associated with increased susceptibility to TDF-FS.

Original languageEnglish (US)
Pages (from-to)82-92
Number of pages11
JournalPharmacogenetics and Genomics
Volume25
Issue number2
DOIs
StatePublished - Feb 13 2015

Keywords

  • Anconi syndrome
  • HIV
  • pharmacogenetics
  • tenofovir
  • transporter

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome'. Together they form a unique fingerprint.

  • Cite this

    Dahlin, A., Wittwer, M., De La Cruz, M., Woo, J. M., Bam, R., Scharen-Guivel, V., Flaherty, J., Ray, A. S., Cihlar, T., Gupta, S. K., & Giacomini, K. M. (2015). A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenetics and Genomics, 25(2), 82-92. https://doi.org/10.1097/FPC.0000000000000110